engue virus (DENV) is a mosquito-borne pathogen that is the causative agent of dengue fever. Severe dengue virus infection is potentially fatal due to hemorrhaging, plasma leakage, and pulmonary shock. The four serotypes of DENV (DENV-1 to DENV-4) are defined by antigenic differences on the viral envelope protein, E, and together, they comprise a species within the Flavivirus genus of the Flaviviridae family. This family of small enveloped viruses with positive-sense RNA genomes encompasses other human pathogens, including West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and hepatitis C virus (HCV). A recent evidence-based study suggests that approximately 300 million DENV infections occur annually (1), and no vaccine or specific antiviral drug is currently available to treat it. DENV vaccine development is a major challenge due to the antibody-dependent enhancement of infection, a phenomenon in which neutralizing antibodies against one DENV serotype can exacerbate disease upon subsequent infection with another serotype (2, 3). A parallel exploration of antiviral strategies to combat DENV infection is therefore crucial.
D
engue virus (DENV) is a mosquito-borne pathogen that is the causative agent of dengue fever. Severe dengue virus infection is potentially fatal due to hemorrhaging, plasma leakage, and pulmonary shock. The four serotypes of DENV (DENV-1 to DENV-4) are defined by antigenic differences on the viral envelope protein, E, and together, they comprise a species within the Flavivirus genus of the Flaviviridae family. This family of small enveloped viruses with positive-sense RNA genomes encompasses other human pathogens, including West Nile virus (WNV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and hepatitis C virus (HCV). A recent evidence-based study suggests that approximately 300 million DENV infections occur annually (1), and no vaccine or specific antiviral drug is currently available to treat it. DENV vaccine development is a major challenge due to the antibody-dependent enhancement of infection, a phenomenon in which neutralizing antibodies against one DENV serotype can exacerbate disease upon subsequent infection with another serotype (2, 3) . A parallel exploration of antiviral strategies to combat DENV infection is therefore crucial.
Resistance to antiviral drugs that act against viral targets occurs rapidly due to the intrinsically high mutation rate of RNA virus polymerases. Host-targeted antivirals that can complement these more traditional antivirals may make the acquisition of resistance to antiviral drugs much less likely and may also offer broad-spectrum activity against phylogenetically related viruses. The interactions between DENV and host lipid biosynthetic, metabolic, trafficking, and signal transducing pathways represent a rich and largely unexplored class of targets for host-targeted antiviral strategies. DENV and other RNA viruses rely entirely on host lipids to supply the membranes essential for the viral replication cycle, and the interaction of viruses with lipid-related processes in the host cell is highlighted by recent studies documenting specific perturbations of these pathways by viruses (4) . In addition, so-called bioactive lipids can regulate cellular processes by modulating signal transduction cascades that may impinge on viral infection. Thus, small molecules that act on host-cell lipid signaling and metabolism are attractive as potential anti-DENV compounds.
To pursue the strategy of targeting host lipid metabolic and signaling pathways important for DENV infection, we screened a panel of bioactive lipids and small-molecule inhibitors of lipid metabolism for activity against DENV. We chose a library enriched for compounds with known safety and bioavailability profiles to increase our likelihood of identifying clinically useful anti-DENV compounds. We present here the identification of the bioactive lipid 4-hydroxyphenyl retinamide (4-HPR) as an inhib-itor of Flavivirus genome replication with activity against DENV in a mouse model of infection.
MATERIALS AND METHODS
Compounds. The bioactive lipid library was acquired from Biomol (Enzo) in library format and supplemented with additional compounds from commercial sources. For follow-up cell culture experiments, chemicals were obtained from commercial sources and resuspended in dimethyl sulfoxide (DMSO): 4-HPR (Biomol), myriocin (Cayman Chemical), cycloheximide (CHX), vitamin C, TTNPB (4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-maphthalenyl)-1-propenyl]benzoic acid), AM580, all-trans-retinoic acid (ATRA) (Sigma), mycophenolic acid (Calbiochem), celgosivir (Dalton and A Chemtek, Inc.), butylated hydroxyanisole (Acros Organics), phorbol 12-myristate 13-acetate (A.G. Scientific), and ketoconazole (Spectrum). The 4-HPR-LXS formulation used for the mouse experiments was described previously (5) and was a generous gift from Barry Maurer.
Compound screen. The compound screen was performed according to previously described procedures (6) . The compounds and data from this primary screen are summarized in Table S1 in the supplemental material. Dose responsiveness, magnitude of effect, and a manual analysis of the primary screening data were used to prioritize compounds for subsequent analyses, yielding a set of 8 preliminary hits (see Table S2 in the supplemental material). Detailed methods are provided in the supplemental material.
Cell lines. Vero cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The HEK293T, BHK21, Huh7.5, C6/36 cells were grown as previously described (7) (8) (9) .
Virus infections and quantification. The virus sources are noted in parentheses: DENV-2 strain NGC (L. Gehrke), Kunjin virus (M. Diamond), Modoc virus (ATCC VR-1260), vesicular stomatitis virus (VSV) (S. Whelan), and poliovirus 1 (PV1) (ATCC VR-1562). Infections of Vero cells with these viruses were performed as previously described for DENV-2 (7, 9) , and viral titers were determined by a plaque formation assay. Hepatitis C virus (HCV) Japanese fulminant hepatitis strain 1 (JFH1) was produced from linearized pJFH-1 plasmid (T. Wakita). Hepatitis C virus (HCV) infections and titer determinations were performed according to published procedures (10, 11) . For influenza virus (A/ PR8/34 [H1N1]) (A. García-Sastre) infections, HEK293T cells were pretreated with 5 M 4-HPR or DMSO for 20 h and then infected at a multiplicity of infection (MOI) of 0.5. Twenty-four hours later, the percentage of infected cells was determined by flow cytometry following staining with murine anti-influenza viral H1 IgG2a (TaKaRa Bio) and a phycoerythrin (PE)-conjugated anti-mouse secondary antibody.
Cell viability. Cell viability was determined using the CellTiter-Glo reagent (Promega), as recommended by the manufacturer.
Antibodies. Hybridomas were used to produce the mouse monoclonal antibodies (MAbs) 6F3.1 (DENV-2 C) (12) and 4G2 (DENV E, ATCC HB-112). MAb E1D8 (DENV-2 nonstructural protein 3 [NS3]) and MAb 9E10 (HCV NS5A) were donated by E. Harris and C. Rice, respectively. Additional antibodies were purchased as follows: anti-double-stranded RNA (dsRNA) mouse antibody J2 from English & Scientific Consulting Bt, rabbit anti-DENV-2-NS5 and mouse anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) antibodies from GeneTex, anti-HCV core antibody from Abcam, horseradish peroxidase-conjugated goat antimouse IgG and anti-rabbit IgG antibodies from Bio-Rad, Alexa Fluor 647-conjugated goat anti-rabbit IgG from Invitrogen, and fluorescein isothiocyanate (FITC) goat-anti mouse from Jackson.
Western blotting. Western blotting analyses were performed as previously described (7) . A densitometric analysis of HCV viral protein, normalized to the GAPDH loading control, was performed by measuring the densities of viral protein and GAPDH from scanned films using ImageJ software (13) .
Immunofluorescence, in situ hybridization, and fluorescence microscopy. In situ hybridization (ISH) using commercially available reagents (Affymetrix) and/or immunofluorescence was performed prior to fluorescence microscopy using the 20ϫ and 60ϫ objectives on a Nikon Eclipse 2000 microscope. The images were acquired with a Hamamatsu Orca-ER camera using MetaMorph and then analyzed with ImageJ software (13) . Detailed methods for these procedures are provided in the supplemental material.
DENV-2 luciferase reporter replicon. Translation and RNA replication assays were performed with pDV2-Fluc WT (WT, wild type), a reporter replicon of DENV-2 strain 16681, as previously described (14, 15) . The plasmid pDV2-Fluc GVD was derived from pDV2-Fluc WT and possesses a mutation in the NS5 polymerase that results in the ablation of the RNA-dependent RNA polymerase activity. The resulting replicon is unable to synthesize viral RNA and can be used as a probe of viral translation (15) . Briefly, after electroporation, the cells were overlaid with DMEM supplemented with 10% (vol/vol) FBS for 5 min, treated with compounds at the indicated final concentrations (5 M 4-HPR, 30 g/ml cycloheximide, 5 M mycophenolic acid [MPA]), and plated. At the indicated times postelectroporation, the cells were washed with phosphate-buffered saline (PBS) and lysed, and the samples were processed for luciferase activity, according to the manufacturer's instructions (catalog no. E1502; Promega). The firefly luciferase signal was read using a PerkinElmer EnVision plate reader.
RNA extraction, real-time quantitative PCR, and Northern blot analyses. Total RNA was isolated from the cell cultures using TRIzol (Invitrogen) or RTL buffer (RNeasy kit; Qiagen) and then analyzed by Northern blotting (16) or used as a template for cDNA synthesis (iScript kit; Bio-Rad), according to the manufacturers' instructions. Quantitative PCR (qPCR) assays utilized the iQ SYBR green Supermix (Bio-Rad) and were performed on a MyiQ iCycler machine (Bio-Rad) as follows: 5 min at 95°C and 40 cycles of 15 s at 95°C and 30 s at 60°C, followed by the melt curve that started at 50°C and increased 0.5°C every 10 s for 90 cycles. The primers were DENV2 Fwd (5=-TCCTAACAATCCCACCAACAGCA) and Rev (5=-AGTTCTGCGTCTCCTGTTCAAGA), GAPDH Fwd (5=-GA GTCAACGGATTTGGTCGT) and Rev (5=-TTGATTTTGGAGGGATCT CG), JFH1 Fwd (5=-TCAGGCAGTACCACAAGGC) and Rev (5=-TCTG CGGAACCGGTGAGTA) (17) , Kunjin primers Fwd 6170 (5=-TGGACG GGGAATACCGACTTAGAGG) and Rev 6278 (5=-ACCCCAGCTGCTG CCACCTT) (18) , and Modoc virus Fwd (5=-GATTCAGGATGGCCCAA GAATC) and Rev (5=-TCATTCTGTCCACCTTCCTACT) (19) .
Quantification of anti-DENV activity in vivo. The animal experiments were reviewed and approved by the Institutional Animal Care and Use Committees of Harvard University and Noble Life Sciences (for Integrated Biotherapeutics). Groups of 10 female 6-to 8-week-old mice deficient in interferon alpha/beta/gamma receptors (catalog no. AG129; Lovelace Respiratory Research Institute) were infected via subcutaneous injection with 1 ϫ 10 4 PFU of the dengue serotype 2 non-mouse-adapted isolate D2Y98P (20, 21) . 4-HPR (fenretinide) formulated as an oral powder in Lym-X-Sorb lipid matrix (4-HPR-LXS), a delivery mode with demonstrated safety that is known to improve the oral bioavailability of 4-HPR (5), was delivered as a suspension via oral gavage at 90 mg/kg of body weight twice daily (BID) for 10 days. Ketoconazole was delivered orally at 25 mg/kg in a suspension with 4-HPR-LXS, BID for 10 days. As a positive control for DENV inhibition, celgosivir hydrochloride was delivered BID via oral gavage at 50 mg/kg for 6 days. The mice were monitored daily for weights, morbidity, and mortality for up to 15 days postinfection (p.i.). On day 7 postinfection, 5 mice from each group were bled via the tail vein for downstream viremia analysis in plasma. Viremia was quantified by a viral plaque formation assay. Statistical significance in the plasma samples was determined in GraphPad Prism (version 5.04) using a 1-way analysis of variance (ANOVA) with a Tukey posttest of the log-transformed titers Ϯ standard deviation.
Lipid analysis. Vero cells were infected with DENV-2 (MOI of 1) and then overlaid with medium containing final concentrations of 5 M 4-HPR and/or 0.250 M myriocin; equivalent concentrations of DMSO were added as negative controls at time zero. At 24 h postinfection, the supernatants were harvested to quantify the titer of infectious virus pro-duced, and whole-cell lipidomes were isolated as described previously (22) . The absolute quantitation of ceramide and dihydroceramide species was accomplished by isotope dilution mass spectrometry using deuterated cholesterol-d7 (Avanti Polar Lipids) as an internal standard added before sample concentration.
Liquid chromatography-mass spectrometry (LC-MS) analyses were performed on an Agilent 6520 accurate-mass quadrupole time of flight (Q-TOF) mass spectrometer configured with an Agilent 1200 series liquid chromatography system and an Agilent electrospray ionization (ESI)-TOF fitted electrospray ionization source. LC-MS analysis was executed in the positive mode, as recommended for ceramides (23) . MassHunter qualitative analysis software (version B.04.00) was used to generate extracted ion chromatograms from the total ion chromatogram from each output (experimental or authentic standard). Identification was based on retention time and the mass-to-charge ratio of sodium adduct ions ([M ϩ Na] ϩ ) (24) . The two-tailed Student's t test was performed to calculate P values. Detailed methods are provided in the supplemental material.
Detection of reactive oxygen species. Vero cells were infected with DENV-2 at an MOI of 1, and medium was added containing the indicated compounds. Reactive oxygen species (ROS) were detected following the addition of 2=,7=-dichlorodihydrofluorescein diacetate (H 2 DCFDA) to a final concentration of 50 M, were incubated for 30 min, and fluorescence was measured with a Wallac EnVision plate reader.
RESULTS
To identify host lipid metabolic and signaling pathways important for DENV infection, we screened a panel of bioactive lipids and small-molecule inhibitors of lipid metabolism for activity against DENV-2 (see Table S1 in the supplemental material). Several compounds inhibited DENV-2 in a dose-responsive manner without significant effects on cell viability (see Table S2 in the supplemental material). The screening hits included compounds known to affect lipid biosynthesis and metabolism, as well as bioactive lipids known to participate in signal transduction. U18666A, an inhibitor of cholesterol synthesis and trafficking that has been reported to inhibit DENV in cell culture (25) , was found in our screen to have anti-DENV-2 activity. Consistent with previous reports documenting the importance of fatty acid synthesis and metabolism in the DENV infectious cycle (25) (26) (27) , a fatty acid synthesis inhibitor (5-(tetradecyloxy)-2-furoic acid [TOFA] ) and an inhibitor of lipid catabolism (17-octadecynoic acid ) were active in our screen. DENV-2 was also sensitive to an inhibitor of protein geranylgeranylation (GGTI 297) and to several signal-transducing bioactive lipids, including 25-hydroxyvitamin D 3 , a prehormone, and arachidonamide, a synthetic analog of arachidonic acid and weak agonist of cannabinoid receptors.
In our screen, DENV was also sensitive to two compounds known to affect ceramide homeostasis, N,N-dimethylsphingosine (N,N-DMS) and 4-hydroxyphenyl retinamide (4-HPR) (Fig. 1A) . N,N-DMS is a naturally occurring metabolite that inhibits sphingosine kinase and increases cellular ceramides via the salvage pathway (28). 4-HPR is a synthetic retinoid that alters ceramide homeostasis via the activation of serine palmitoyltransferase and ceramide synthase (29, 30) and the inhibition of dihydroceramide desaturase (31) . Ceramides and ceramide metabolism have been implicated in DENV replication (32) and DENV-induced apoptosis (33) (34) (35) , making 4-HPR an attractive antiviral molecule that interacts with known lipid pathways important for DENV infection. Additionally, 4-HPR has been investigated in the clinic as a potential treatment or preventative agent for various cancers (36, 37) , psoriasis (38) , obesity-associated insulin resistance (39) , and macular degeneration (40) . The known safety and bioavailability profiles of 4-HPR therefore make it an attractive candidate for repurposing as an antiviral agent.
4-HPR prevents the steady-state accumulation of DENV genomic RNA. Our primary screen allowed for viral spread between cells, and we therefore asked whether 4-HPR could inhibit DENV-2 within a single round of infection. We quantified the antiviral effect of 4-HPR when Vero cells were infected with DENV-2 at a high multiplicity of infection (MOI of 10) and monitored over a single infectious cycle. 4-HPR caused a dose-dependent reduction in the steady-state accumulation of intracellular viral proteins (see Fig. S1 in the supplemental material) and a profound reduction in the yield of infectious DENV-2 (Fig. 1B) , with an EC 90 value (defined as the concentration of 4-HPR that reduces the yield of infectious DENV-2 produced during a single cycle by 10-fold) of 2.0 M under these experimental conditions (see Fig. S2 in the supplemental material). The antiviral activity of 4-HPR was comparable in potency to that of mycophenolic acid (MPA) (Fig. 1B) and celgosivir (see Fig. S2 ), two established inhibitors of DENV-2 (41-44), and this was not due to general cytotoxicity, since cell viability was unaffected at concentrations of Յ10 M (Fig. 1B, gray bars) . For all subsequent experiments, we used 4-HPR at a concentration of 5 M, unless indicated otherwise.
To investigate the effect of 4-HPR on the viral replication cycle, we examined its effects on the kinetics of viral protein expression, genomic RNA accumulation, and infectious particle production in one-step growth curve experiments. 4-HPR delayed the appearance of infectious virions in the culture supernatant (Fig. 1C) and significantly reduced the quantity of infectious virions released, even when multiple cycles of infection were allowed to occur (data not shown). This effect was paralleled by a delay in the appearance of detectable levels of DENV-2 genomic RNA (Fig. 1C) and DENV-2 core and NS3 proteins (see Fig. S1 in the supplemental material) in the cell lysates, suggesting that 4-HPR affects early events in the infectious cycle (viral entry, translation, and genome replication) rather than virion assembly or release. Although 4-HPR inhibits human immunodeficiency virus (HIV) by promoting the endocytosis of virions and preventing fusion at the plasma membrane (45), DENV-2 naturally enters the cell via endocytosis (46) , and membrane fusion occurs in late endosomes (47, 48) . We therefore suspected that 4-HPR is unlikely to inhibit DENV-2 and HIV by an identical mechanism.
To assess the effects of 4-HPR on the translation and replication of the DENV-2 genome, we used a subgenomic reporter replicon (15) (Fig. 2A) that permits an analysis of these processes in the absence of viral entry, assembly, and egress. In this system, luciferase activity predominantly reflects the translation of the input replicon RNA at early times following electroporation (Ͻ12 h) but is a marker of both viral translation and steady-state replication of the viral RNA at later time points (Ͼ24 h) (14) (15) (16) . At 6 h postelectroporation, 4-HPR-treated cells exhibited luciferase activity comparable to that of the DMSO-treated controls, indicating that 4-HPR does not inhibit the translation of input replicon RNA (Fig. 2B ). This interpretation is further supported by the absence of an effect of 4-HPR in a mutant replicon system in which RNA replication cannot occur due to the substitution of a catalytic amino acid residue in the NS5 RNA-dependent RNA polymerase (see Fig. S3 in the supplemental material) . In contrast, 4-HPR prevented the steady-state accumulation of replicon RNA, as evidenced by the near absence of luciferase activity at 48 and 72 h postelectroporation in the 4-HPR-treated cells (Fig. 2C) . We verified this effect by Northern blotting (see Fig. S3 ) and in situ hybridization experiments to detect the DENV-2 genomic RNA via fluorescence microscopy. The treatment of DENV-2-infected cells with 4-HPR resulted in fewer cells positive for DENV-2 RNA and qualitatively weaker fluorescence intensities for the DENV-2 RNA and the NS3 protein it encodes compared to that in the DMSO-treated control samples at 24 h postinfection (Fig. 2D) . Thus, 4-HPR inhibits a process required for the steady-state accumulation of the DENV-2 genome.
4-HPR inhibits replication of the DENV-2 genome via a mechanism distinct from that of existing inhibitors. Because the assays described above detect total DENV-2 RNA and do not distinguish DENV-2 RNA present in genome replication complexes from RNA present in translation complexes, incoming virions, or newly assembled viral particles, we next asked whether 4-HPR affects DENV-2 RNA replication or another aspect of viral RNA metabolism. Genome replication of DENV-2 and other Flaviviridae proceeds through a double-stranded RNA (dsRNA) intermediate recognized by antibodies specific for double-stranded RNA and detectable by immunofluorescence microscopy as cytoplasmic puncta (49) . The treatment of DENV-2-infected cells with 4-HPR reduced the signal for dsRNA to barely detectable levels, consistent with a robust inhibition of DENV-2 genome replication (Fig. 2E) . The inhibitory effects of 4-HPR or MPA on the dsRNA replication intermediate and the production of infectious virions were largely alleviated when compound treatment was delayed until 6 or 10 h postinfection ( Fig. 2F and G) , kinetics consistent with targeting of the same viral process by both compounds.
DENV-2 RNA replication depends on numerous factors and processes. These include the viral RNA-dependent RNA polymerase NS5, host cell nucleotide metabolism, and the replication complex scaffold protein NS4B. The inhibition of host IMP dehydrogenase by MPA limits viral RNA replication by depleting intracellular GTP (41, 50) . Small molecules targeting the viral NS4B protein (51, 52) and host Fyn kinase (16) also inhibit DENV-2 genome replication through mechanisms that have not been fully characterized. However, resistance mutations mapping to the same region of NS4B (16, 51) suggest that Fyn and NS4B inhibitors act via related mechanisms. The inhibition of viral replication by 4-HPR is distinct from these known mechanisms, since neither the addition of GTP nor the presence of a dasatinib resistance mutation (NS4B T108I) rescued DENV-2 replication in the presence of 4-HPR (Fig. 3A and B) . Further, we observed that 4-HPR inhibited West Nile (Kunjin), Modoc, and hepatitis C (HCV) viruses in a manner associated with steady-state decreases in viral genomic RNA (Fig. 3C to E) . This suggests that the host factor or pathway targeted by 4-HPR is conserved in its interactions across members of the Flaviviridae family. Modest inhibition by 4-HPR extended to vesicular stomatitis virus (VSV) (Fig. 3F ) and poliovirus 1 (PV1) (Fig. 3G) but not to influenza virus (strain A/PR8/ 34) (Fig. 3H) . Therefore, 4-HPR targets a process that is critically important for steady-state viral RNA replication among the Flaviviridae, of some importance to PV1 and VSV, and not relevant to influenza virus.
Anti-DENV-2 activity of 4-HPR does not require the accumulation of long-chain dihydroceramides or reactive oxygen species. 4-HPR is known to have multiple targets, some of which overlap with naturally occurring retinoids (39) . These include the retinoic acid receptors (RARs) (53, 54) , retinol-binding proteins (RBPs) (39, 55) , mammalian target of rapamycin (mTor) (56) , and dihydroceramide desaturase (DES) (29, 31, 57, 58) , among others. Because we found that all-trans retinoic acid (ATRA) and other analogs of ATRA did not inhibit DENV-2 (see Fig. S4 in the supplemental material), we explored the possibility that DENV-2 inhibition occurs through a pathway unique to 4-HPR. 4-HPR causes the accumulation of long-chain dihydroceramides via the activation of serine palmitoyl transferase (SPT) and dihydroceramide synthase (DHCerS) and the inhibition of dihydroceramide desaturase (DES) (29, 31, 57, 58) (Fig. 1A) . Further, DENV-induced apoptosis of transformed cell lines is associated with perturbations in ceramide homeostasis (33) (34) (35) 59) , and replication membranes isolated from a DENV-2-infected mosquito cell line are enriched with long-chain ceramides and dihydroceramides (32) . We therefore investigated the effects of long-chain ceramides and dihydroceramides on DENV-2 replication, and we asked whether the antiviral activity of 4-HPR may be due to its effects on ceramide homeostasis.
We first examined the effects of DENV-2 infection on the steady-state abundance of long-chain ceramide and dihydroceramide species in mammalian cells using liquid chromatographymass spectrometry analysis of whole-cell lipidomes. DENV-2 infection of Vero cells (MOI of 1) was associated with 2.1-to 1.2-fold enrichment of long-chain ceramides (d18:1/16:0 and d16:1/16:0) and dihydroceramides (d18:0/16:0 and d16:0/16:0), respectively ( Fig. 4A and B) . The effect on these lipid species was modest and does not appear to be required for DENV-2 replication, since the viral titers (Fig. 4C ) and steady-state viral protein expression levels (see Fig. S5 in the supplemental material) were unchanged in the presence of myriocin, an inhibitor of de novo ceramide biosynthesis that reduced the abundances of these long-chain ceramide and dihydroceramide species below the level observed in the uninfected cells ( Fig. 4A and B ; see also Fig. S5 in the supplemental  material) . The absence of a detectable proviral effect for the d16: 1/16:0 ceramide in the primary screen (see Table S1 in the supplemental material) is also consistent with this interpretation.
We next investigated whether long-chain ceramides or dihydroceramides are critical for the antiviral activity of 4-HPR. Consistent with its effects on uninfected cells, 4-HPR caused Ͼ100-fold enrichments of d18:0/16:0 and d16:0/16:0 dihydroceramide species (Fig. 4E ) and more modest increases in d18:1/16:0 and d16:1/16:0 ceramides in DENV-2-infected cells (Fig. 4D) , but it did not affect cholesterol or sphingomyelin (data not shown). The effect of 4-HPR on long-chain dihydroceramides was blocked in the presence of myriocin, which reduced the abundances of these lipids to the levels observed for untreated DENV-2-infected cells (Fig. 4E compared to 4B) . However, myriocin failed to block the antiviral activity of 4-HPR (Fig. 4F) . Our data therefore strongly suggest that the effect of 4-HPR on long-chain dihydroceramides is independent of its antiviral activity.
In addition to its effects on ceramide metabolism, 4-HPR is known to induce the accumulation of reactive oxygen species (ROS) (60) . To determine whether the induction of ROS by 4-HPR might play a role in its activity against DENV-2, we treated cells with the antioxidants vitamin C and butylated hydroxyanisole (BHA). These antioxidants efficiently depleted ROS (see Fig.  S6 in the supplemental material) but did not affect viral titer or protein production in cells treated with DMSO. Although vitamin C appeared to slightly enhance the antiviral activity of 4-HPR, the magnitude of this effect was small, and we did not attempt to quantify or further characterize it since it was not observed with BHA and therefore did not appear to be due to its antioxidant properties. Since neither vitamin C nor BHA reversed the inhibition of DENV-2 by 4-HPR ( in a murine model of DENV infection. D2Y98P is a non-mouseadapted strain of DENV-2 that undergoes productive viral replication and dissemination and induces relevant clinical manifestations and lethality when administered at a low viral dose to mice lacking type I and II interferon receptors (AG129) (20, 21) . The mice were inoculated subcutaneously with 1 ϫ 10 4 PFU of D2Y98P virus and treated with 4-HPR starting 24 h prior to infection and continuing for 10 days postinfection. We observed that 4-HPR dosed at 180 mg kg Ϫ1 per day, which was sufficient for a predicted plasma concentration of 15 M (61), caused a significant 1.73-log 10 reduction in peak viremia relative to that of animals treated with vehicle alone (Fig. 5) . The in vivo anti-DENV-2 activity of 4-HPR was comparable to that of celgosivir (50 mg/kg/ day, 0.80 log 10 ), which was previously shown to be efficacious in murine models of lethal DENV-2 infection (43, 44) and which is currently in a phase Ib clinical trial as an anti-DENV-2 agent. The coadministration of ketoconazole improves 4-HPR pharmacokinetics by slowing the conversion of 4-HPR into 4-oxo-4-HPR (61) and led to slightly reduced plasma viremia compared to that in mice treated with 4-HPR alone. This interpretation is supported by the observation that 4-oxo-4-HPR was a less potent inhibitor of DENV-2 than 4-HPR and that ketoconazole had no anti-DENV-2 activity in cell culture (see Fig. S7 in the supplemental material) .
Together, these data demonstrate that 4-HPR is an inhibitor of DENV-2 infection in vivo.
DISCUSSION
In the work presented here, we have identified 4-HPR as an inhibitor of viral replication with activity against members of the family Flaviviridae. Our experiments with cultured cells show that 4-HPR affects steady-state viral genome replication and does so via a host factor or pathway that is important for viral replication in vivo. Although known effectors of 4-HPR-mediated cancer cell apoptosis, including long-chain dihydroceramides and ROS, are not required for antiviral activity, the host factor or pathway mediating this activity appears to be conserved in its interactions with the Flaviviridae and possibly with a subset of other RNA viruses. Finally, the effect of 4-HPR on viremia in a mouse model of DENV infection suggests that it may be useful as a countermeasure against DENV infection in humans.
Further investigation of the mechanism by which 4-HPR inhibits DENV genomic replication will generate insights into the mechanism of flavivirus replication and will uncover potential strategies for the inhibition of this process. Although 4-HPR is known to affect several different cellular pathways, the recent study by Fraser et al. (62) showing that 4-HPR inhibits the interaction of the DENV NS5 protein with nuclear importin-␣/␤1 in a biochemical assay and also activates the unfolded protein response in DENV-infected cells (62) is particularly noteworthy. Preliminarily, our observation of the immunofluorescence of the nuclear NS5 protein in cells treated with 4-HPR (Fig. 2E ) is at odds with this explanation of the activity of 4-HPR against DENV. Nonetheless, determining conclusively whether 4-HPR inhibits the nuclear import of NS5 and the relationship of this phenomenon to the antiviral activity of 4-HPR is of high priority. This stated, our observation of activity against hepatitis C and Modoc viruses suggests that an additional molecular target conserved in its function across the Flaviviridae is also required for maximal antiviral activity. While the unfolded protein response is one candidate, a careful consideration of the other known pharmacological properties of 4-HPR may also provide insights into its novel antiviral mechanism of action.
The molecular targets of 4-HPR relevant to cancer (36, 37) , macular degeneration (40), psoriasis (38) , obesity-associated insulin resistance (39) , and other diseases are still elusive, despite considerable investigation over the previous decades. A recurring theme complicating these studies has been the polypharmacology of 4-HPR. Consequently, medicinal chemistry to define distinct structure-activity relationships characteristic of the different biological activities of 4-HPR would facilitate a determination of the biochemical and molecular bases underlying these phenomena. In addition, this would enable the synthesis of chemical entities with only the desired activity for use as chemical probes in basic virology studies and as potential antiviral agents.
While our study focused on quantifying the effect of 4-HPR on DENV replication in vivo, the study by Fraser et al. (62) documented the effect of 4-HPR on survival in another murine model of DENV infection without measuring the effect of the compound on viremia or viral burden. Although neither study (50 mg/kg) as an oral suspension to AG129 mice infected with DENV-2 D2Y98P. Plasma samples were collected from DENV-2-infected mice, and infectious virus titers were measured by plaque formation assay. Viremia at 7 days postinfection was lower in mice treated with celgosivir or with 4-HPR. Statistical significance in the plasma samples was determined using a 1-way ANOVA with a Tukey posttest of log-transformed titers Ϯ standard deviation. n.s, nonsignificant.
alone correlates the inhibition of DENV by 4-HPR with increased survival, together, they provide compelling evidence that 4-HPR is an effective inhibitor of DENV replication in vivo and that this antiviral activity is efficacious in reducing DENVassociated disease in an animal model. The well-established safety and tolerability in humans and the panflaviviral activity of 4-HPR are positive factors in considering it as a potential candidate for drug repurposing, even in the absence of a fully characterized target and mechanism of action. We began this study with the idea that an investigation of the interaction of DENV with host lipid biosynthetic, metabolic, trafficking, and signal transducing pathways might lead to the discovery of antiviral agents with broad activities against phylogenetically related viruses and with high barriers to resistance. The work we present here illustrates the potential of this approach for exploring the interaction of viral pathogens with host lipid pathways and for identifying new antiviral agents.
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